الفهرس 
? Hepatocellular CarcinomaOnly 14 pages are availabe for public view
 |  | from | 155 |  |  |
| | | from | 155 | | |
Abstract
HCC is the sixth most common malignancy and the third most common cause of cancer related death. Since HCC usually develops in a damaged liver, the prognosis of HCC depends not only on tumor progression but also on the degree of liver dysfunction. In Egypt, liver cancer forms 23.81 of the total malignancies. HCC constitutes 70.48% of all liver tumors among Egyptians.
Chemoembolization (TACE) is the most widely used primary treatment for unresectable HCC and the recommended first line-therapy for patients at intermediate stage of the disease.
In contrast to other cancers, the prognosis of patients with HCC is not solely related to tumour stage. Accordingly, different prognostic systems assessing liver function and tumour stage have been developed such as the Okuda staging, CLIP score and the BCLC. The previous staging systems have been developed for the classification of patients with HCC, but none have been specifically developed to predict outcomes of therapy for HCC. Previous studies have compared staging systems for their ability to predict the survival of patients treated with TACE, but there is no evidence which is best.
The hepatoma arterial-embolization prognostic (HAP) score was recently qualified as a prognostic tool that classifies patients into four strata based on the four most statistically significant predictors of Overall survival (OS); albumin, bilirubin, AFP and tumour size.
Modified versions of HAP score were established to improve the overall survival of the patients who will undergo TACE/TAE.